This study aimed to examine the efficacy and safety of nirmatrelvir/ritonavir (Paxlovid) for
coronavirus disease 2019 (COVID‐19). PubMed, Cochrane Library, Web of Science …

COVID-19 patients at risk of severe disease may be treated with neutralising monoclonal
antibodies (mAbs). To minimise virus escape from neutralisation these are administered as …

This article systematically presents the current clinically significant therapeutic
developments for the treatment of COVID-19 by providing an in-depth review of molecular …

Background COVID-19 severity is associated with its respiratory manifestations. Neutralising
antibodies against SARS-CoV-2 administered systemically have shown clinical efficacy …

At the end of 2019, a novel coronavirus rapidly spread throughout the world, resulting in a
global pandemic. The virus was designated severe acute respiratory syndrome coronavirus …

Background Machine learning algorithms are essential for predicting severe outcomes
during public health crises like COVID-19. However, the dynamic nature of diseases …

We read with great interest that monoclonal antibody (mAb) cocktail may serve as an
effective and targeted therapeutic strategy in the treatment of patients with COVID-19. 1 …

Passive antibody therapies, typically administered via parenteral routes, have played a
crucial role in the initial response to the COVID-19 pandemic. However, the ongoing …

Background The ongoing global epidemic of coronavirus disease 2019 (COVID-19) has
created a serious public health problem. The selection of safe and effective therapeutic …

Some COVID-19 patients are unable to clear their infection or are at risk of severe disease,
requiring treatment with neutralising monoclonal antibodies (nmAb) and/or antivirals. The …